HTRA1 and CARASIL: The pathophysiology underlying CARASIL is associated with homozygous or compound heterozygous mutations that lead to the functional impairment of the HTRA1 gene.[11] In terms of the pathogenic mechanism related to heterozygous mutations of HTRA1, Nozaki et al[12] proposed the existence of a dominant-negative effect.